

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-016-999
		(CAM:	417451-999016)
			IDX 1017

CONSENT OF ASSIGNEE TO CORRECT INVENTORSHIP UNDER 37 C.F.R.
1.48(a) WITH STATEMENT UNDER 37 C.F.R. 3.73(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

L'Université Montpellier II, an assignee of the above-referenced application, hereby consents to the correction of inventorship under 37 C.F.R. 1.48(a), removing Richard Storer as an inventor.



L'Université Montpellier II states that it is an assignee of less than the entire right, title and interest in the patent application/patent identified above by virtue of an Assignment Agreement dated March 4, 2009. The Assignment Agreement was recorded in the United States Patent and Trademark Office on May 6, 2009 at Reel 022644, Frame 0923. The undersigned (whose title is supplied below) does declare, under penalty of perjury, that he is authorized to act on behalf of L'Université Montpellier II.

Respectfully submitted,

Date: 26/05/2009

Name: DANIELE HERIN

Title: PRESIDENT



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LaColla, et al.
Title : 2' and 3'-Nucleoside Prodrugs for Treating
Flaviviridae Infections
Customer No. : 57263

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

CONSENT OF ASSIGNEE UNDER 37 C.F.R. § 3.73(b) FOR CORRECTION OF
INVENTORSHIP

Dear Sir:

Assignee, Università Degli Studi Di Cagliari, does hereby consent to the correction of inventorship, the Petition for which is being filed concurrently herewith, which seeks to remove Richard Storer as an inventor in U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections", as listed in Appendix A attached hereto. The undersigned does declare, under penalty of perjury, that he is authorized by Università Degli Studi Di Cagliari to make this Consent of Assignee for Correction of Inventorship. A copy of Assignment documents originally submitted in the parent application U.S. 60/392,351 on January 9, 2003 is enclosed.

Respectfully submitted,

UNIVERSITA DEGLI STUDI DI CAGLIARI




io, Ufficiale Rogante
dell'Università degli Studi di
Cagliari, che la firma apposta in mia
qualità di Prof. Adolfo Lai nato a
Cagliari il 28.07.1948, della cui identità
personale sono certo è autentica

L'Ufficiale Rogante Sostituto
Dr. Achille Filiberto Putzu


Signature

21 DEC 2004
Date



ADOLFO LAI
Name

PRO RETTORE UNIVERSITA' CAGLIARI
Title

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LaColla, et al.
Title : 2' and 3'-Nucleoside Prodrugs for Treating
Flaviviridae Infections
Customer No. : 57263

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**CONSENT OF ASSIGNEE UNDER 37 C.F.R. § 3.73(b) FOR CORRECTION OF
INVENTORSHIP**

Dear Sir:

Assignee, Idenix Pharmaceuticals Inc., does hereby consent to the correction of inventorship, the Petition for which is being filed concurrently herewith, which seeks to remove Richard Storer as an inventor in U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections", as listed in Appendix A attached hereto. The undersigned does declare, under penalty of perjury, that he is authorized by Idenix Pharmaceuticals Inc. to make this Consent of Assignee for Correction of Inventorship. A copy of Assignment documents originally submitted in the parent application U.S. 60/392,351 on January 9, 2003 is enclosed.

Respectfully submitted,

IDENIX PHARMACEUTICALS INC.


Signature

10/5/04
Date

JEAN-PIERRE SOMMADOSSI, Ph.D.

CHAIRMAN AND CEO

IDENIX PHARMACEUTICALS, INC.
Name Title

APPENDIX A

Title	Application No.	Filing Date	Attorney Docket No.	Applicant
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	10/609,298	June 27, 2003	06171.105059 IDX 1017	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,442	December 6, 2004	06171.105126 IDX 1017 CON 2	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,466	December 6, 2004	06171.105126 IDX 1017 CON 3	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,440	December 6, 2004	06171.105126 IDX 1017 CON 4	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,443	December 6, 2004	06171.105126 IDX 1017 CON 5	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,446	December 6, 2004	06171.105126 IDX 1017 CON 6	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,472	December 6, 2004	06171.105126 IDX 1017 CON 7	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,444	December 6, 2004	06171.105126 IDX 1017 CON 8	LaColla et al.

10EN1X

0V62810

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LaColla, et al.
Title : 2' and 3'-Nucleoside Prodrugs for Treating
Flaviviridae Infections
Customer No. : 57263

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**CONSENT OF ASSIGNEE UNDER 37 C.F.R. § 3.73(b) FOR CORRECTION OF
INVENTORSHIP**

Dear Sir:

Assignee, Centre National De La Recherche Scientifique, does hereby consent to the correction of inventorship, the Petition for which is being filed concurrently herewith, which seeks to remove Richard Storer as an inventor in U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections", as listed in Appendix A attached hereto. The undersigned does declare, under penalty of perjury, that he is authorized by Centre National De La Recherche Scientifique to make this Consent of Assignee for Correction of Inventorship. A copy of Assignment documents originally submitted in the parent application U.S. 60/392,351 on January 9, 2003 is enclosed.

Respectfully submitted,

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Directeur du Service du Transfert de
Technologies

Date

Frédéric FOUBERT

Name

Title

APPENDIX A

Title	Application No.	Filing Date	Attorney Docket No.	Applicant
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	10/609,298	June 27, 2003	06171.105059 IDX 1017	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,442	December 6, 2004	06171.105126 IDX 1017 CON 2	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,466	December 6, 2004	06171.105126 IDX 1017 CON 3	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,440	December 6, 2004	06171.105126 IDX 1017 CON 4	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,443	December 6, 2004	06171.105126 IDX 1017 CON 5	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,446	December 6, 2004	06171.105126 IDX 1017 CON 6	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,472	December 6, 2004	06171.105126 IDX 1017 CON 7	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,444	December 6, 2004	06171.105126 IDX 1017 CON 8	LaColla et al.